FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
|Articles|April 22, 2015
- Melanoma (Issue 4)
- Volume 4
- Issue 1
Toxicity of Immunotherapies in Melanoma
Author(s)Jeffrey S. Weber, MD, PhD
Jeffrey S. Weber, MD, PhD, a senior member at Moffitt Cancer Center, discusses toxicities associated with immunotherapies for the treatment of patients with melanoma.
Advertisement
Jeffrey S. Weber, MD, PhD, a senior member at Moffitt Cancer Center, discusses toxicities associated with immunotherapies for the treatment of patients with melanoma.
Articles in this issue
over 11 years ago
Comparing Two Doses of Ipilimumabover 11 years ago
New Standards Needed to Lessen Surgery Delays in Melanomaover 11 years ago
Gene Removal May Pose Future Treatment in Advanced Melanomaover 11 years ago
The Development of T-VEC for Melanomaover 11 years ago
The Role of Macrophages in BRAF Inhibitor ResistanceAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5